MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.97 +2.02%

+$0.08 today

Market cap
$125.90M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.72M

Average 0.98M

MGNX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

MacroGenics, Inc.NASDAQ: MGNX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 63.45M shares rose 0.8% year over year, in line with the +0.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.8% holds above the trailing-twelve-month pace of +0.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
63.45M+0.5% QoQ
Last fiscal yearDec 2025
63.16M+0.9% YoY
LTMMar 2026
63.26M+0.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.8%——
1 year+0.9%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
63.16M USD
Year-over-year change
+0.9%
4-year CAGR
+1.3%

Weighted Avg Shares (Diluted) vs competitors

How MGNX compares with its peers on the latest reported figures

  • MGNX's LTM Mar 2026 weighted avg shares (diluted) of 63.26M shares is the 7th highest of the 11 companies compared; the peer median is 69.02M shares.
  • Its year-over-year change of +0.8% is the 10th highest of 11, against a peer median of +10.3%.
  • Over three fiscal years its annual growth of +0.9% compares with a peer median of +16.5%.
MGNX Competitors Peer median
Weighted Avg Shares (Diluted) for MGNX and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
WHWKWhitehawk Therapeutics IncLTM Mar 202669.18M +155.7%+40.1%
IFRXInflaRx N.V.LTM Mar 202668.86M +14.8%+15.0%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 202642.44M +3.8%+2.8%
COYACoya Therapeutics, Inc.LTM Mar 202616.73M +5.9%+18.9%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
Peer median (excluding MGNX) 69.02M+10.3%+16.5%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.64M150.02M57.19M148.34M149.5M
Cost of Revenue2.65M7.38M8.22M12.3M43.18M
Gross Profit72.99M142.63M48.97M136.04M106.32M
Gross Margin96.5%95.1%85.6%91.7%71.1%
Research & Development214.58M207.03M166.58M177.19M140M
Selling, General & Admin63.01M58.95M52.19M71.05M39.16M
Operating Expenses275.79M264.05M217.22M246.62M179.16M
Depreciation & Amortization11.26M11.87M9.65M7.54M7.17M
EBITDA(190.86M)(107.89M)2.02M(57.37M)(59.61M)
EBITDA Margin-252.3%-71.9%3.5%-38.7%-39.9%
Operating Income(202.8M)(121.42M)(168.24M)(110.58M)(72.84M)
Operating Margin-268.1%-80.9%-294.2%-74.5%-48.7%
Interest Income680K1.7M9.69M9.42M3.4M
Interest Expense001.43M1.12M8.51M
Other Income / Expenses680K1.66M159.19M44.56M(2.45M)
Income Before Tax(202.12M)(119.76M)(9.06M)(66.02M)(75.29M)
Pre-Tax Margin-267.2%-79.8%-15.8%-44.5%-50.4%
Income Tax Expense000944K(672K)
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Net Margin-267.2%-79.8%-15.8%-45.1%-49.9%
EPS (Basic)(3.18)(1.95)(0.15)(1.07)(1.18)
EPS (Diluted)(3.18)(1.95)(0.15)(1.07)(1.18)
Weighted Avg Shares59.94M61.41M61.93M62.62M63.16M
Weighted Avg Shares (Diluted)59.94M61.43M61.93M62.62M63.16M

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$1.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.